通过细胞疗法开发人员阻止的合并建议

比利时细胞疗法公司已经宣布了杂种药（法国巴黎）在9月6日的公告，该公告宣布了与骨治疗疗法的可能合作伙伴关系的讨论，该公司已遵守比利时细胞疗法公司，该公司的重点是解决矫形医学和其他医疗需求疾病。

Responding the next day, Bone therapeutics (Gosselies, Belgium) stated that the French biopharma company had only made ‘very preliminary contacts’ to examine a combination of certain activities between the two companies and that ‘the opportunity for further discussions with Hybrigenics would be carefully evaluated by the board of directors of Bone Therapeutics, taking into account the interests of its shareholders and other stakeholders.’

Hybrigenics在公告中表示，它在2020年初非正式地接触了骨治疗药，强调了两家公司之间的许多可能的协同作用，但当时在讨论结束时“感到惊讶”。

It added that the decision to renew proposals was based on the conviction that ‘a merger of certain activities of the two companies would create additional value for the shareholders’ as the technologies developed by both companies ‘are very complementary (allogeneic and autologous approaches to the use of stem cells) and address markets with fairly similar issues’.

骨治疗药的组合包括用于临床前计划的细胞疗法，以针对骨科状况的中期临床发育进行免疫调节。它的核心技术基于其同种异体细胞和基因治疗平台，具有分化的骨髓的间充质基质细胞（MSCS。

杂种及其子公司构成了诊断医学系统小组的DMS生物技术部门，即生物技术，肿瘤学，再生医学和抗衰老医学领域的领先战略发展。它的重点是使用脂肪组织细胞，尤其是干细胞，用于开发治疗溶液。

更多信息在线的